Company intelligence / Profile preview

MedAlliance

Nyon, Vaud, Switzerlandmedalliancenyc.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

MedAlliance developed the SELUTION SLR™ sirolimus-eluting balloon platform for coronary and peripheral artery disease. The technology uses biodegradable polymer MicroReservoirs to provide controlled, sustained release of sirolimus for up to 90 days. Clinical programs have led to regulatory approvals including CE Mark; the company has an extensive clinical study program supporting global commercialization.

Therapeutic areas: Cardiovascular
Modalities: DeviceDrug-device combination productSmall molecule
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

SELUTION SLR

Commercial

Indications: Peripheral artery disease, Coronary artery disease

Partnerships

Cordis

Beyond the preview

Go deeper on MedAlliance.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedAlliance.

Explore the full profile